Clinical Study

Efficacy of Autologous Bone Marrow Concentrate for Knee Osteoarthritis with and without Adipose Graft

Table 5

Adjusted odds ratios and 95% confidence intervals for lower extremity functional scale improvement (ΔLEFS ≥ 9 points), decreased NPS score (VAS drop ≥ 2 points), and reporting ≥50% improvement on the improvement rating scale (group A: bone marrow concentrate (BMC), group B: BMC and adipose graft, BMI: body mass index, LEFS: lower extremity functional scale, NPS: numeric pain scale, KL: Kellgren-Lawrence scale, indicates a statistically significant odds ratio, and Ref: referent group).

LEFS outcomesNPS outcomesImprovement rating scale outcomes
Baseline LEFS ≤ 45 ()Baseline LEFS = 46–70 ()Baseline NPS  ≥ 5 ()Baseline NPS = 2–4 ()()

Group B0.8 (0.3–2.1)1.3 (0.5–3.6)1.3 (0.5–3.2)1.6 (0.6–4.6)0.7 (0.4–1.1)
Group A1 (Ref)1 (Ref)1 (Ref)1 (Ref)1 (Ref)
Age > 600.4 (0.2–1.3)1.1 (0.4–2.9)0.4 (0.1–1.3)2.2 (0.6–8.5)1.4 (0.9–2.3)
Age 51–600.4 (0.1–1.2)0.6 (0.2–2)0.3 (0.1–1.2)2.5 (0.6–10.5)1.5 (0.9–2.4)
Age ≤ 501 (Ref)1 (Ref)1 (Ref)1 (Ref)1 (Ref)
BMI ≥ 303 (1.08.6)*0.7 (0.1–4.1)0.9 (0.3–3)0.3 (0.1–1.2)1 (0.6–1.8)
BMI 25–29.93.5 (1.29.8 )*1.7 (0.7–4.2)1 (0.3–3.2)0.4 (0.1–1.4)1.2 (0.8–1.9)
BMI < 251 (Ref)1 (Ref)1 (Ref)1 (Ref)1 (Ref)
Female3.4 (1.5-8.2) * 1.3 (0.6–3.2)2.6 (1.06.6)*1.1 (0.4–2.9)1.4 (0.9–2.1)
Male1 (Ref)1 (Ref)1 (Ref)1 (Ref)1 (Ref)
KL10.9 (0.3–3)1.6 (0.4–6.1)1 (0.3–3.2)0.9 (0.2–4.6)1.7 (0.9–2.9)
KL20.9 (0.3–2.7)2.2 (0.6–8.6)1 (0.3–3.2)0.8 (0.1–4.2)2.2 (1.23.9)*
KL3-41 (Ref)1 (Ref)1 (Ref)1 (Ref)1 (Ref)